Frontiers in Neuroscience (Apr 2023)
Brain iron content in cerebral amyloid angiopathy using quantitative susceptibility mapping
- Breni Sharma,
- Breni Sharma,
- Breni Sharma,
- Andrew E. Beaudin,
- Andrew E. Beaudin,
- Andrew E. Beaudin,
- Emily Cox,
- Emily Cox,
- Emily Cox,
- Feryal Saad,
- Feryal Saad,
- Feryal Saad,
- Feryal Saad,
- Krista Nelles,
- Myrlene Gee,
- Richard Frayne,
- Richard Frayne,
- Richard Frayne,
- Richard Frayne,
- Richard Frayne,
- Richard Frayne,
- David G. Gobbi,
- David G. Gobbi,
- David G. Gobbi,
- David G. Gobbi,
- David G. Gobbi,
- Richard Camicioli,
- Richard Camicioli,
- Eric E. Smith,
- Eric E. Smith,
- Eric E. Smith,
- Eric E. Smith,
- Cheryl R. McCreary,
- Cheryl R. McCreary,
- Cheryl R. McCreary,
- Cheryl R. McCreary,
- Cheryl R. McCreary
Affiliations
- Breni Sharma
- Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
- Breni Sharma
- Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada
- Breni Sharma
- Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada
- Andrew E. Beaudin
- Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
- Andrew E. Beaudin
- Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada
- Andrew E. Beaudin
- Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada
- Emily Cox
- Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
- Emily Cox
- Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada
- Emily Cox
- Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada
- Feryal Saad
- Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
- Feryal Saad
- Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada
- Feryal Saad
- Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada
- Feryal Saad
- Seaman Family MR Research Centre, University of Calgary, Calgary, AB, Canada
- Krista Nelles
- Department of Medicine (Neurology), University of Alberta, Edmonton, AB, Canada
- Myrlene Gee
- Department of Medicine (Neurology), University of Alberta, Edmonton, AB, Canada
- Richard Frayne
- Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
- Richard Frayne
- Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada
- Richard Frayne
- Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada
- Richard Frayne
- Seaman Family MR Research Centre, University of Calgary, Calgary, AB, Canada
- Richard Frayne
- Department of Radiology, University of Calgary, Calgary, AB, Canada
- Richard Frayne
- Calgary Image Processing and Analysis Centre, University of Calgary, Calgary, AB, Canada
- David G. Gobbi
- Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
- David G. Gobbi
- Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada
- David G. Gobbi
- Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada
- David G. Gobbi
- Department of Radiology, University of Calgary, Calgary, AB, Canada
- David G. Gobbi
- Calgary Image Processing and Analysis Centre, University of Calgary, Calgary, AB, Canada
- Richard Camicioli
- Department of Medicine (Neurology), University of Alberta, Edmonton, AB, Canada
- Richard Camicioli
- Neuroscience and Mental Health Institute, University of Alberta, Edmonton, AB, Canada
- Eric E. Smith
- Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
- Eric E. Smith
- Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada
- Eric E. Smith
- Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada
- Eric E. Smith
- Seaman Family MR Research Centre, University of Calgary, Calgary, AB, Canada
- Cheryl R. McCreary
- Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
- Cheryl R. McCreary
- Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada
- Cheryl R. McCreary
- Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada
- Cheryl R. McCreary
- Seaman Family MR Research Centre, University of Calgary, Calgary, AB, Canada
- Cheryl R. McCreary
- Department of Radiology, University of Calgary, Calgary, AB, Canada
- DOI
- https://doi.org/10.3389/fnins.2023.1139988
- Journal volume & issue
-
Vol. 17
Abstract
IntroductionCerebral amyloid angiopathy (CAA) is a small vessel disease that causes covert and symptomatic brain hemorrhaging. We hypothesized that persons with CAA would have increased brain iron content detectable by quantitative susceptibility mapping (QSM) on magnetic resonance imaging (MRI), and that higher iron content would be associated with worse cognition.MethodsParticipants with CAA (n = 21), mild Alzheimer’s disease with dementia (AD-dementia; n = 14), and normal controls (NC; n = 83) underwent 3T MRI. Post-processing QSM techniques were applied to obtain susceptibility values for regions of the frontal and occipital lobe, thalamus, caudate, putamen, pallidum, and hippocampus. Linear regression was used to examine differences between groups, and associations with global cognition, controlling for multiple comparisons using the false discovery rate method.ResultsNo differences were found between regions of interest in CAA compared to NC. In AD, the calcarine sulcus had greater iron than NC (β = 0.99 [95% CI: 0.44, 1.53], q < 0.01). However, calcarine sulcus iron content was not associated with global cognition, measured by the Montreal Cognitive Assessment (p > 0.05 for all participants, NC, CAA, and AD).DiscussionAfter correcting for multiple comparisons, brain iron content, measured via QSM, was not elevated in CAA compared to NC in this exploratory study.
Keywords
- cerebral amyloid angiopathy
- Alzheimer’s disease
- iron
- neuroimaging
- quantitative susceptibility mapping
